Clinical Trials Browser

Terminated × Interventional × VTX-2337 × Clear all

NCT03906526 2023-02-24

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Phase 1 Terminated

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04272333 2022-04-14

Intratumoral Microdosing of Motolimod in HNSCC

Phase EARLY_PHASE1 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02124850 2019-10-25

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Phase 1 Terminated

Squamous Cell Carcinoma of Head and Neck

NCT01289210 2019-09-25

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Phase 1/2 Terminated

2 enrolled 4 charts

Lymphoma

NCT02650635 2018-09-05

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Phase 1 Terminated

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms